Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Ironwood Pharmaceuticals ( IRWD ) stock is buoyant today, up >15%, despite the CMS announcing the list price of its drug Linzess will be slashed from 2027, from $568 per month, to $136.Edmund Ingham is a biotech co ...

-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. for patent infringement rel ...

Eli Lilly and Company ( LLY ) became the first pharmaceutical company in history to reach a valuation of $1 trillion , and virtually the entire story is based on the boom in GLP-1 drugs for obesityHi, I'm Martin, I focus on maintaining a delta neutral portfolio. I want to be long/short at the same time and benefit from market volatility. I specialize in using options through which I enter and exit trades. I look for market opportunities primarily in small companies, and my search takes me into the waters of ...

Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk's blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts... ...

Patients could soon access higher-dose injections.Shares of Novo Nordisk (NVO +3.42%) are gaining on Monday, up 3.5% as of 2:40 p.m. ET. The jump comes as the S&P 500 and the Nasdaq Composite gained 0.8% and 0.9%, respectively. The Danish drugmaker submitted an application today seeking regulatory approval for a higher dose of its blockbuster weight-loss drug, Wegovy.NYSE : NVONovo NordiskToday's Change( 3.42 %) $ 1.61Current Price$ 48.67Key Data PointsMarket Cap$159BDay's Range$ 48.19 - $ 49.0252wk Range$ ...

On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management.NVO is among today's top performers. See the trading setup hereThe new, higher dose of Wegovy (semaglutide 7.2 mg) is currently under review with the European Medicines Agency, in the U.K., and several other countries.In the EU, Novo Nordisk expects a regulatory decision in Q1 2026.Under the C ...

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.Lyme disease is a bacterial infection transmitted to humans by infected ticks, often presenting with an early “bull’s-eye” rash and flu-like symptoms such as fever, headache, and fatigue.The results showed a strong anamnestic immune response and a favorable safety profile six months after a third booster dose (month 48) in all age groups, confirmin ...

Drug pricing has emerged as a key topic to watch for pharmaceutical companies and investors in 2025. As President Donald Trump pushes for lower medicine prices for Americans, the sector is facing additional pricing pressure from a Biden-era law called the Inflation Reduction Act.The IRA, voted into law in 2022, allows the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for a number of drugs each year for patients in Medicare, the federal health insurance program for seniors. It's now maki ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Wednesday.The Dow traded up 0.75% to 47,466.81 while the NASDAQ rose 0.93% to 23,240.04. The S&P 500 also rose, gaining, 0.82% to 6,821.37.Check This Out: Jim Cramer: This Communication Services Stock Is A Buy, Recommends Holding On To Howmet AerospaceLeading and Lagging SectorsInformation technology shares jumped by 1.5% on Wednesday.In trading on Wednesday, communication services stocks fell by 0.4%. ...